

EPV0534

The sublingual use of atropine in the treatment of clozapine-induced sialorrhea

H. Becerra Darriba

Centro Salud Mental De Tudela - Hospital Reina Sofía, Servicio Navarro de Salud - Osasunbidea., Tudela (Navarra), Spain
doi: 10.1192/j.eurpsy.2021.2061

Introduction: Clozapine is a second-generation antipsychotic indicated in treatment-resistant schizophrenia. Patients taking clozapine are likely to experience an increase in salivation or sialorrhea. Clozapine-induced sialorrhea (CIS) may lead to sleep disturbances or aspiration pneumonia. Treatment options include locally administered anticholinergic medication with atropine ophthalmic drops applied sublingually.

Objectives: To review the current evidence for the effectiveness, safety, side effects and dosage of sublingual application of atropine in reducing or resolving of CIS.

Methods: Systematic review. Data were obtained from PubMed/Medline, EMBASE, PsycINFO, Cochrane Plus, Trip Database, Science Direct and Scopus searches of English-language articles, without restriction for date of publication and study design, reporting the sublingual use of atropine in the treatment of CIS. Large clinical studies with appropriate statistical methods and recruited adults were preferred.

Results: 12 selected articles (of 458 references) consisted entirely of case reports and case series. A total of 29 patients with CIS were reported, of whom 24 responded favorably to sublingually administered atropine drops 1% (1-2 drops a day). One limitation of its utilization is the dose-related dry mouth, which can be addressed by lowering the number of drops administered. CIS can occur at different clozapine doses, in various stages of treatment.

Conclusions: The reviewed articles suggest that the use of sublingual atropine is a promising local treatment for CIS. Oral anticholinergic and alpha-2 agonist medications have been used to treat CIS with variable efficacy, but can cause systemic anticholinergic side effects. Further experimental research is needed.

Disclosure: No significant relationships.

Keywords: CIS; sublingual atropine; clozapine-induced sialorrhea

EPV0535

Therapeutic use of psychedelic drugs in depression disorders

M. Trigo

Psychiatry, Centro Hospitalar Universitário do Algarve, Faro, Portugal
doi: 10.1192/j.eurpsy.2021.2062

Introduction: Depression is one of the most prevalent mental illnesses, leading to important personal distress and economic consequences. Treatment is long, often involving psychotherapy and pharmacological treatment, and relapses are frequent. Used mostly for treatment of mood disorders and alcohol dependence, drugs such as lysergic acid diethylamide (LSD) were studied in the 1950's and showed therapeutic promise in attenuating depressive symptoms. However, in the 1960s all major psychedelic research

programs were ended. Recently, there is a renewed research interest in these drugs, considering its antidepressant potential.

Objectives: To review current knowledge on the therapeutic uses of psychedelic drugs such as LSD in depression disorders.

Methods: Review of the most recent literature regarding the therapeutic potential of psychedelic drugs such as LSD in depression disorders. The research was carried out through the UptoDate, PubMed, MedLine, ScienceDirect and SpringerLink databases, using the terms “LSD”, “psychedelic drugs” and “depression disorders”, until December 2020.

Results: As in past scientific studies, data of recent clinical research shows that the use of LSD relieves distress concerning death, particularly in terminally ill oncologic patients, and addictions including alcoholism and nicotine. There is more limited data concerning the use of classic hallucinogens to treat depression and anxiety disorders.

Conclusions: Although research has shown many of the neurobiological and psychological effects of classic hallucinogens on humans, the studies that have been completed to date are not sufficient to establish clinically relevant effects. Despite further research is needed, the outcomes are encouraging, and larger, well-designed, placebo-controlled trials are now underway or being planned.

Disclosure: No significant relationships.

Keywords: depression disorders; psychedelic drugs; LSD; Psychopharmacology

Psychophysiology

EPV0536

Extrapyramidal symptoms as a consequence of organophosphate poisoning: Insights from a clinical case

J. Martins Correia*, S. Freitas Ramos, M.I. Fonseca
Marinho Vaz Soares, B. Jesus, D. Cruz E Sousa and S. Caetano

Department Of Psychiatry And Mental Health, Local Health Unit of
Guarda, Guarda, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2063

Introduction: The development of an extrapyramidal syndrome (EPS) is assumed to be a potential and important consequence of organophosphate poisoning (OP). Even though its causal relationship is firmly established, the information available in the literature regarding the orientation to be given is scarce, and its approach remains shrouded in a significant degree of uncertainty. Catatonia, as a neuropsychiatric condition, may present a marked overlap with the set of extrapyramidal symptoms developed after OP. Does the overlap between the symptoms seen in catatonia and in EPS make differential diagnosis fundamental or does it have no relevance in relation to the approach to be established?

Objectives: To discuss the therapeutic approach to be implemented in the extrapyramidal symptoms resulting from OP and reflect on the overlap between catatonia and EPS.

Methods: Presentation of a clinical case and review of the literature.